Cycloferon for frequently recurring genital herpes: a review of the evidence base and clinical prospects

Petrov A.Yu.; Tataurshchikova N.S.; Kovalenko A.L.; Maksimova A.V.

doi:https://doi.org/10.17116/immunology2025101139

Petrov A.Yu.

Golikov Research Center of Toxicology

ORCID: 0000-0001-6204-0145

Tataurshchikova N.S.

RUDN University

ORCID: 0000-0002-3486-8188

Kovalenko A.L.

Golikov Research Center of Toxicology

ORCID: 0000-0003-3695-2671

Maksimova A.V.

RUDN University

Cycloferon for frequently recurring genital herpes: a review of the evidence base and clinical prospects

Authors:

Petrov A.Yu., Tataurshchikova N.S., Kovalenko A.L., Maksimova A.V.

More about the authors

Journal: Journal of Adaptive Medical Immunology and Public Health Issues. 2025;1(1): 39‑44

DOI: 10.17116/immunology2025101139

Read: 244 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Petrov AYu, Tataurshchikova NS, Kovalenko AL, Maksimova AV. Cycloferon for frequently recurring genital herpes: a review of the evidence base and clinical prospects. Journal of Adaptive Medical Immunology and Public Health Issues. 2025;1(1):39‑44. (In Russ.)
https://doi.org/10.17116/immunology2025101139

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Post-exposure prophylaxis of influenza and ARVI. Results of a double-blind, placebo-controlled clinical trial of Meglumine acridone acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medicine. 2025;(4):57-66

Prostate involvement in granulomatosis with polyangiitis. Russian Journal of Archive of Pathology. 2025;(3):82-87

Abstract:

Frequently recurring genital herpes (FRGH) is a serious medical and social problem that significantly reduces patients’ quality of life. Herpes simplex virus type 2 (HSV-2), less commonly type 1 (HSV-1), persists in the ganglia of the nervous system, causing a chronic recurrent course of the disease. In recent years, researchers have been focusing on immunomodulatory drugs that can influence the immune response and, thereby, control viral replication and reduce the frequency of exacerbations. One such drug is Cycloferon (meglumine acridonacetate), an inducer of endogenous interferon with antiviral and immunomodulatory effects. This review is devoted to the analysis of existing data on the effectiveness of Cycloferon in the treatment of frequently recurring genital herpes, the assessment of its potential advantages and limitations, and the identification of promising areas for further research in this field. Our goal is to provide a scientifically sound review that will help clinicians make decisions about the appropriateness of using Cycloferon in the complex therapy of FRGH.

Keywords:

genital herpes

recurring

pathology

meglumine acridonacetate

Authors:

Petrov A.Yu.

Golikov Research Center of Toxicology

ORCID: 0000-0001-6204-0145

Tataurshchikova N.S.

RUDN University

ORCID: 0000-0002-3486-8188

Kovalenko A.L.

Golikov Research Center of Toxicology

ORCID: 0000-0003-3695-2671

Maksimova A.V.

RUDN University

Received:

11.07.2025

Accepted:

26.08.2025

Close metadata

References:

Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the American Academy of Dermatology. 2007;57(5):737-766. https://doi.org/10.1016/j.jaad.2007.06.027
Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and accumulate in latently infected nervous tissue. Journal of Experimental Medicine. 2003;198(5):719-730 https://doi.org/10.1016/s1074-7613(03)00112-2
Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurology. 2007;6(11):1015-1028. https://doi.org/10.1016/s1474-4422(07)70267-3
Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670-2702. https://doi.org/10.1080/21505594.2021.1982373
Malashenkova I, Didkovsky N. Principles of immunocorrective therapy for secondary immunodeficiencies associated with chronic viral-bacterial infection. RMJ. 2002;21:973. (In Russ.).
Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. IL-12 administration during primary genital herpes simplex virus type 2 (HSV-2) infection reduces HSV-2 latency and subsequent recurrences. Journal of Immunology. 2003;170(8):4241-4249.
Freeman ML, Sheridan BS. The role of CD4(+) T cells in herpes simplex virus type 1 latency and reactivation. Journal of Neurovirology. 2012;18(1):1-9.
Nesterova IV. Congenital and acquired interferonopathies: differentiated approaches to interferon-corrective therapy. Detskie infekcii. 2017;16(2): 50-53. (In Russ.). https://doi.org/10.22627/2072-8107-2017-16-2-50-53
Samuel CE. Antiviral actions of interferons. Clinical Microbiology Reviews. 2001;14(4):778-809. https://doi.org/10.1128/CMR.14.4.778-809.2001
Crow YJ, Manel N. Monogenic type I interferonopathies: Mendelian disorders unveiling immune pathways. Nature Reviews Immunology. 2015;15(7):422-432. https://doi.org/10.1038/nri3850
Zhang Y, Stein SC, Kindrick DL, et al. TLR3 deficiency in human fetal astrocytes impairs innate immunity against herpes simplex virus type 1. Journal of Immunology. 2013;190(11):5603-5613.
Rönnblom L, Alm GV. Systemic lupus erythematosus and interferon-alpha. Autoimmunity. 2001;33(1):3-13.
Blaszczyk KN, Rychlowski JM, Gorski A, et al. Increased expression of interferon-alpha-induced genes in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. Clinical and Experimental Immunology. 2005;140(2):345-352.
de Veer MJ, Holko M, Frevel M, Walker E, Der SD, Silverman RH. Functional classification of interferon-stimulated genes. Journal of Interferon and Cytokine Research. 2001;21(Suppl 1):S1-S9.
Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Hood HM, Kruskel L. Interferon-alpha enhances JAK-STAT signaling in cells of the immune system. Cellular Immunology. 1997;179(1):1-11.
Hall JC, Rosen A, Kahn JE, Lorentzen DF, Jiang HR. Interferon-stimulated gene expression is an early and sensitive marker of lupus disease activity. Annals of the New York Academy of Sciences. 2008;1143:192-210.
Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, Oojageer A, Anderson B, Pizzino A, Helman G, Abdel-Hamid MS, Abdel-Salam GM, Ackroyd S, Aeby A, Agosta G, Albin C, Allon-Shalev S, Arellano M, Ariaudo G, Aswani V, Babul-Hirji R, Baildam EM, Bahi-Buisson N, Bailey KM, Barnerias C, Barth M, Battini R, Beresford MW, Bernard G, Bianchi M, Billette de Villemeur T, Blair EM, Bloom M, Burlina AB, Carpanelli ML, Carvalho DR, Castro-Gago M, Cavallini A, Cereda C, Chandler KE, Chitayat DA, Collins AE, Sierra Corcoles C, Cordeiro NJ, Crichiutti G, Dabydeen L, Dale RC, D’Arrigo S, De Goede CG, De Laet C, De Waele LM, Denzler I, Desguerre I, Devriendt K, Di Rocco M, Fahey MC, Fazzi E, Ferrie CD, Figueiredo A, Gener B, Goizet C, Gowrinathan NR, Gowrishankar K, Hanrahan D, Isidor B, Kara B, Khan N, King MD, Kirk EP, Kumar R, Lagae L, Landrieu P, Lauffer H, Laugel V, La Piana R, Lim MJ, Lin JP, Linnankivi T, Mackay MT, Marom DR, Marques Lourenço C, McKee SA, Moroni I, Morton JE, Moutard ML, Murray K, Nabbout R, Nampoothiri S, Nunez-Enamorado N, Oades PJ, Olivieri I, Ostergaard JR, Pérez-Dueñas B, Prendiville JS, Ramesh V, Rasmussen M, Régal L, Ricci F, Rio M, Rodriguez D, Roubertie A, Salvatici E, Segers KA, Sinha GP, Soler D, Spiegel R, Stödberg TI, Straussberg R, Swoboda KJ, Suri M, Tacke U, Tan TY, te Water Naude J, Wee Teik K, Thomas MM, Till M, Tonduti D, Valente EM, Van Coster RN, van der Knaap MS, Vassallo G, Vijzelaar R, Vogt J, Wallace GB, Wassmer E, Webb HJ, Whitehouse WP, Whitney RN, Zaki MS, Zuberi SM, Livingston JH, Rozenberg F, Lebon P, Vanderver A, Orcesi S, Rice GI. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1 and IFIH1. American Journal of Medical Genetics. Part A. 2015;167A(2):296-308. https://doi.org/10.1002/ajmg.a.36887
Yan Y, Jiang Y, Liu Y, et al. Elevated serum interferon-alpha levels in patients with autoimmune diseases. Journal of Clinical Immunology. 2006;26(6):529-536.
Crow YJ. Type I interferonopathies: Mendelian mimics of acquired immune disorders. Current Opinion in Immunology. 2011;23(6):703-709.
Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annual Review of Immunology. 2005;23:307-336.
Vavilenkova YA. Modern concepts of the interferon system//Bulletin of the Smolensk State Medical Academy. Vestnik Smolenskoj gosudarstvennoj medicinskoj akademii. 2012;2:74-82. (In Russ.).
Ershov FI. Interferony` i ix induktory` (ot molekul do lekarstv). M.: GEOTAR-Media; 2005. (In Russ.).
Kazantsev VS, Afanasyeva OI, Kuzmina TYu, et al. Clinical and immunological efficacy of cycloferon in the complex therapy of recurrent genital herpes. Voprosy` virusologii. 2000;5:32-35. (In Russ.).
Malova IO, Khamitova GR, Efimova EE. Evaluation of the effectiveness of cycloferon in the complex therapy of recurrent genital herpes. Sibirskij medicinskij zhurnal (Irkutsk). 2010;95(4):146-149. (In Russ.).